Spectrum Pharmaceuticals Inc
F:NTR
Spectrum Pharmaceuticals Inc
Research & Development
Spectrum Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Spectrum Pharmaceuticals Inc
F:NTR
|
Research & Development
-$43.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
3%
|
CAGR 10-Years
0%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
Research & Development
-$98m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-17%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
Spectrum Pharmaceuticals Inc
Glance View
Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of late-stage clinical and commercial products. The company is headquartered in Henderson, Nevada and currently employs 163 full-time employees. The firm's product portfolio consists of in-development drug products for the treatment of cancer patients. Its pipeline products include ROLONTIS, Poziotinib and Anti-CD20-IFNa. ROLONTIS (eflapegrastim injection), is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib, is a pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. Anti-CD20-IFNa, is an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for treating relapsed or refractory non-Hodgkin's lymphoma (NHL) patients.
See Also
What is Spectrum Pharmaceuticals Inc's Research & Development?
Research & Development
-43.4m
USD
Based on the financial report for Mar 31, 2023, Spectrum Pharmaceuticals Inc's Research & Development amounts to -43.4m USD.
What is Spectrum Pharmaceuticals Inc's Research & Development growth rate?
Research & Development CAGR 10Y
0%
Over the last year, the Research & Development growth was 40%. The average annual Research & Development growth rates for Spectrum Pharmaceuticals Inc have been 16% over the past three years , 3% over the past five years .
